Market Overview

UPDATE: ISI Group Raises PT to $27 on Hologic Following Guidance Raise

Share:
Related HOLX
Hologic Receives Extended FDA Clearance for SculpSure in US
Hologic Wins FDA Approval for Genius 3D Mammography Exam

ISI Group maintained Hologic (NASDAQ: HOLX) with a Strong Buy rating and raised the price target from $25.50 to $27.00.

ISI Group commented, "Going forward, we expect increased adoption of 3D Tomo (as presaged by the continued sequential backlog increase) and Panther (Diagnostics) to drive growth upside. In the NT, receipt of a potential CMS reimbursement code for 3D Tomo will be a significant catalyst. Given our thesis for a new product cycle accelerating growth, we are reiterating our Strong Buy rating of HOLX shares and raising our price target from $25.50 to $27.00."

Hologic closed at $23.25 on Monday.

Latest Ratings for HOLX

DateFirmActionFromTo
Feb 2017NeedhamUpgradesHoldBuy
Feb 2017Bank of AmericaDowngradesBuyNeutral
Jan 2017Deutsche BankInitiates Coverage OnBuy

View More Analyst Ratings for HOLX
View the Latest Analyst Ratings

Posted-In: ISI GroupAnalyst Color Price Target Analyst Ratings

 

Related Articles (HOLX)

View Comments and Join the Discussion!